Proactive Investors - Run By Investors For Investors

ANGLE device central to new, ground-breaking cancer research

Scientists at the University of Basel, Switzerland, used ANGLE’s Parsortix liquid biopsy to isolate metastatic circulating tumour cell clusters
cancer cells from taken by an electron microscope
The work may ultimately help prevent the spread of the killer disease, a process called metastasis

ANGLE PLC (LON:AGL) has revealed its cancer detection device played an important role in research that may one day help prevent the spread of cancer around the body.

Scientists at the University of Basel, Switzerland, used ANGLE’s Parsortix liquid biopsy to isolate metastatic circulating tumour cell clusters - a group of cancer and other cells tethered together as a single mass.

WATCH: ANGLE plc's Parsortix device plays critical role in ground-breaking new cancer research

Once these clusters were identified, the Basel team, led by Professor Nicola Aceto, was able to treat them with repurposed drugs already on the market.


Eye-catching was the fact that this approach led to a “near total elimination” of metastasis in animal models.

As most people will know, metastasis is where cancer spreads to other parts of the body via the bloodstream. It is responsible for more than 90% of all cancer-related deaths.  

The detail of the research undertaken by the Cancer Metastasis Laboratory was published Friday (Jan 11) as a peer-reviewed article in the prestigious journal, Cell.

ANGLE is seeking US Food & Drug Administration approval for Parsortix.


Chief executive, Andrew Newland, said: "The ground-breaking CTC cluster work undertaken over the last three years by the University of Basel, one of ANGLE's leading customers, highlights completely new clinical uses for the Parsortix system with the potential to play a central role in dramatically improving patient outcomes.

“This is a key potential application for Parsortix liquid biopsy once we receive FDA clearance.

“Our ultimate aim is for the Parsortix system to be routinely used for all cancer patients in the future."

---Repeated from Thursday evening---

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use